Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2025 08:00 ET | Source: PolyPid Ltd.

PolyPid to Report Second Quarter 2025 Financial Results and Operational Highlights on August 13, 2025

PETACH TIKVA, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced...
July 15, 2025 10:00 ET | Source: The Finance Herald

Finance Herald Publishes Coverage of PolyPid's Groundbreaking New 60-Day GLP-1 Delivery Tech

New York, July 15, 2025 (GLOBE NEWSWIRE) -- The Finance Herald, a leading news and analysis site today published a new deep dive report covering market developments, with a focus on PolyPid and...
July 15, 2025 08:00 ET | Source: PolyPid Ltd.

PolyPid Unveils a Long-Acting GLP-1 Receptor Agonists Delivery Platform Targeting the Diabetes and Weight Loss Market

PolyPid's proprietary and clinically validated, prolonged-release drug delivery technology aims to subcutaneously deliver GLP-1 for approximately 60 days, compared to current standard of care of...
June 11, 2025 09:42 ET | Source: PESG Research

PESG Research Update: PolyPid's SHIELD II Trial Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary...
June 11, 2025 09:40 ET | Source: PESG Research

PESG Research Update: PolyPid SHIELD’s II Delivers Transformative Phase 3 Topline Results - Paradigm Shift in Surgical Infection Prevention

On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary...
June 09, 2025 08:54 ET | Source: BriefCast

BriefCast Publishes Transcript: PolyPid Ltd. SHIELD II Phase 3 Trial Topline Results Call Transcript

In a call hosted today, June 9, 2025, PolyPid Ltd. unveiled highly successful topline results from its SHIELD II Phase 3 trial of D-PLEX100 for preventing surgical site infections (SSIs) in abdominal...
May 30, 2025 10:12 ET | Source: PESG Research

PESG Research Report: Revolutionary Surgical Infection Prevention: PolyPid’s D-PLEX100 Approaches Critical Phase 3 Data Readout

New York, May 30, 2025 (GLOBE NEWSWIRE) -- PESG Research is releasing a report today examining PolyPid Ltd.*, an innovative late-stage biopharmaceutical company developing revolutionary localized...